



Nexstim Plc: Managers' Transactions, Järnefelt

Company Announcement, Helsinki, 22 May 2023 at 10:30 AM (EEST)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:

Person subject to the notification requirement

Name: Gustaf Järnefelt

Position: Other senior manager

Issuer: Nexstim Oyj

LEI: 743700S7ZIOLNMHZ6Y27

Notification type: INITIAL NOTIFICATION

Reference number: 32080/4/6

Transaction date: 2023-05-17

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: 2023A

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 15796 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 15796 Volume weighted average price: 0 EUR

Transaction date: 2023-05-17

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: 2023B

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 15550 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 15550 Volume weighted average price: 0 EUR

Transaction date: 2023-05-17

Outside a trading venue

Nexstim

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

Name of the instrument: 2023C

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 15303 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 15303 Volume weighted average price: 0 EUR

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

The Company's Certified Advisor is Erik Penser Bank.

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the Navigated Brain Therapy (NBT[®]) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT[®] system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com